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INTEREST OF AMICUS CURIAE1 
 
AARP is a nonpartisan, nonprofit organization 
dedicated to addressing the needs and interests of 
people age fifty and older.  AARP seeks through 
education, advocacy, and service to enhance the 
quality of life for all by promoting independence, 
dignity, and purpose.  In its efforts to promote 
independence, AARP works to foster the health and 
economic security of individuals as they age by 
attempting to ensure the availability of quality and 
economical health coverage.  AARP has a long history 
of advocating for access to affordable health care and 
for controlling costs without compromising quality.   
 
Access to affordable health care is particularly 
important to the older population, which has higher 
rates of chronic and serious health conditions.  
Genetic tests are capable of diagnosing a variety of 
diseases, assessing the risk of future disease, and 
enabling treatment to be tailored to individual 
genetic variations.  Patents such as those present in 
this case significantly elevate the cost of genetic 
testing, and prohibit diagnosis and treatment based 
on second medical opinions.  In light of the 
significance of the issue presented in this case, AARP 
                                                            
1 In accordance with Supreme Court Rule 37.6, AARP states 
that: (1) no counsel to a party authored this brief, in whole or in 
part; and (2) no person or entity, other than AARP, its members 
and its counsel have made a monetary contribution to the 
preparation or submission of this brief. Written consent of the 
parties has been obtained and will be filed with the Clerk of the 
Court pursuant to Supreme Court Rule 37.3. 
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respectfully submits this amicus curiae brief in 
support of the petitioners. 
 
SUMMARY OF THE ARGUMENT 
 
Gene patents threaten public health by 
chilling scientific research and preventing patients 
from obtaining necessary diagnostic procedures and 
treatments.  Additionally, the monopoly created by 
gene patents allows the patent holder to charge fees 
that are unaffordable to many people, effectively 
denying them life-saving medical treatment.  
 
 DNA molecules and human genetic sequences 
are natural phenomena that, when discovered, are 
not the kinds of “discover[ies]” that 35 U.S.C. § 101 
protects.  Gene patents do not promote the progress 
of science and are not in the public interest. 
 
ARGUMENT 
 
I. Gene Patents Threaten Public Health and 
Are Not in the Public Interest 
 
The Court has long recognized that “the rights 
and welfare of the community must be fairly dealt 
with and effectually guarded” in the patent system.   
Kendall v. Winsor, 62 U.S. (21 How.) 322, 329 (1858). 
More recently, the Court held that courts must 
consider the public impact when considering 
injunctive relief in patent cases.  eBay Inc. v. 
MercExchange, L.L.C., 547 U.S. 388, 391 (2006).   
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 The ultimate object of the patent laws has 
always been to benefit, not harm, the public.  See 
Kendall, 62 U.S. at 329 (“Considerations of individual 
emolument can never be permitted to operate to the 
injury of [the rights and welfare of the community].”). 
“A patent by its very nature is affected with a public 
interest. As recognized by the Constitution, it is a 
special privilege designed to serve the public purpose 
of promoting the ‘Progress of Science and useful 
Arts.’”  Precision Instrument Mfg. Co. v. Auto. Maint. 
Mach. Co., 324 U.S. 806, 816 (1945) (quoting U.S. 
Const. art. I, § 8, cl. 8). 
 
A. Gene Patents Have a Chilling Effect on 
Scientific Research 
 
Unfortunately, gene patents and the 
omnipresent threat of multi-million dollar patent 
lawsuits can significantly inhibit genetic research.  
An example of how gene patents can stymie 
research—even when defendants succeed in 
defeating the patents—are the multiple suits brought 
by the Alzheimer’s Institute of America, Inc. (“AIA”) 
concerning research and testing of early onset 
Alzheimer’s Disease.  The AIA reportedly purchased 
a patent from Michael Mullan, a biomedical 
researcher, who patented a human DNA sequence 
used in mouse models of early-onset Alzheimer’s 
disease.  Erika C. Hayden, Patent Dispute Threatens 
US Alzheimer’s Research, 472 Nature 20, 20 (2011), 
available at 
http://www.nature.com/news/2011/110405/pdf/472020
a.pdf.  The sequence encodes a mutation which 
causes early-onset Alzheimer’s.  Id. 
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The AIA sued private companies, academic 
institutions, and federally funded laboratories for 
infringing this patent.  See Alzheimer’s Inst. of Am., 
Inc. v. Avid RadioPharmaceuticals, et al., No. 2:10-
cv-06908-TJS (E.D. Pa. filed Nov. 24, 2010); 
Alzheimer’s Inst. of Am., Inc. v. Elan 
Pharmaceuticals, Inc., No. 3:10-cv-00482-EDL (N.D. 
Cal. filed Feb. 2, 2010); Alzheimer’s Inst. of Am., Inc. 
v. CoMentis, Inc., No. 5:09-cv-01366-F (W.D. Okla. 
filed Dec. 14, 2009); Alzheimer’s Inst. of Am., Inc. v. 
Pfizer, Inc., No. 4:09-cv-01026-CAS (E.D. Mo. filed 
June 30, 2009).  In the Avid RadioPharmaceuticals 
case, Avid’s counsel indicated that Avid incurred over 
$6.5 million in attorney’s fees and $222,000 in costs 
trying the case, which resulted in a defense verdict.  
Bill of Costs, Avid RadioPharmaceuticals, et al., No. 
2:10-cv-06908-TJS, ECF No.: 318-1; Decl. of L. Scott 
Burwell, Avid RadioPharmaceuticals, et al., No. 2:10-
cv-06908-TJS, ECF No.: 317-4.  Even in the AIA 
cases dismissed before trial, cost bills alone filed by 
defendants totalled over $130,000, exclusive of 
attorney’s fees. See Bill of Costs of Elan, Elan 
Pharmaceuticals, Inc., No. 3:10-cv-00482-EDL, ECF 
No.: 323 ($57,555.80); Bill of Costs of Elie Lilly, Elan 
Pharmaceuticals, Inc., No. 3:10-cv-00482-EDL, ECF 
No.: 319 ($3,710.59); Bill of Costs, CoMentis, Inc., No. 
5:09-cv-01366-F, ECF No.: 182 ($69,482.53).  These 
costs and fees can be devastating—particularly for 
universities and other non-profit institutions.  As one 
Alzheimer’s researcher noted, these lawsuits 
“‘constitute a large drain on valuable scientific 
resources at a time when scientific funds are 
increasingly tight.’”  Hayden, supra, at 20 (quoting 
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Benjamin Wolozin, Alzheimer’s researcher, Boston 
University).  
 
Not surprisingly, then, gene patents have 
made laboratories hesitant to conduct promising 
genetic research. A survey of more than 130 genetic 
laboratories revealed that fifty-three percent of 
respondents elected to forgo developing or performing 
a genetic test for clinical or research purposes 
because of a pre-existing patent.  Mildred K. Cho et 
al., Effects of Patents and Licenses on the Provision of 
Clinical Genetic Testing Services, 5 J. Molecular 
Diagnostics 3, 5 (2003); see also John F. Merz, 
Disease Gene Patents: Overcoming Unethical 
Constraints on Clinical Laboratory Medicine, 45 
Clinical Chemistry 324, 327 (1999) (“The knowledge 
that a patent application has been filed can influence 
the decision to spend the time and resources to 
develop a clinical test because of the uncertain risk 
that a patent holder will later prevent the laboratory 
from continuing to provide this service.”); Alzheimer 
Research Forum, Workshop Explores Intellectual 
Property Issues in Alzheimer’s Disease (Nov. 4, 2003), 
http://www.alzforum.org/new/detail.asp?id=901 
(hypothesizing that “academic investigators may feel 
constrained from crossing a patented AD mouse 
model with other strains, even though such 
experiments might help uncover additional genes 
involved in neurodegeneration.  Further, 
investigators and their institutions may be concerned 
about sharing or providing a mouse model that may 
be covered by a patent to their colleagues, who might 
use the model to identify a promising drug for AD.”).  
Invalidating gene patents would eliminate the 
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significant risk of costly patent litigation, thereby 
encouraging genetic research.  The research is 
particularly important for Alzheimer’s Disease 
because there is currently no known curative 
measure available.  Alzheimer’s Ass’n, 2012 
Alzheimer’s Disease Facts and Figures 12 (2012), 
http://www.alz.org/downloads/facts_figures_2012.pdf. 
 
B. Gene Patents Impede the Ability of 
Patients to Obtain a Second Opinion 
 
Information gained from genetic tests can have 
a profound impact on medical decision-making.  For 
many, the results from genetic testing can be life-
altering.  Kathy L. Hudson et al., Oversight of US 
Genetic Testing Laboratories, 24 Nature 
Biotechnology 1083, 1083 (2006).   
 
Obtaining a second opinion is critical because 
even the most qualified, highly skilled medical 
professional can make a mistake or differ in opinions.  
QuantialMD, Physician Perspectives on Preventing 
Diagnostic Errors 3 (2011), available at 
http://www.quantiamd.com/q-qcp/QuantiaMD_ 
PreventingDiagnosticErrors_Whitepaper_1.pdf.  A 
new report from QuantialMD found that almost half 
of 6,400 physicians surveyed said they encounter 
diagnostic errors—missed, late, or wrong diagnoses—
at their practice at least monthly.  Id.  About two-
thirds said that up to ten percent of misdiagnoses 
they have experienced have directly resulted in 
patient harm.  Id.  
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In the absence of a second opinion, laboratory 
errors and inaccurate test results can result in 
“misdiagnosis, inappropriate and/or delayed 
treatment, anxiety and in rare cases, even death.”   
Hudson, supra, at 1089.  Independent confirmatory 
testing is especially important, given the 
“implications for major medical decisions, such as 
whether to have a mastectomy or surgical removal of 
the ovaries.”  U.S. Dep’t of Health & Human Servs., 
Gene Patents and Licensing Practices and Their 
Impact on Patient Access to Genetic Tests: Report of 
the Secretary’s Advisory Committee on Genetics, 
Health, and Society 44 (Apr. 2010) [hereinafter 
SACGHS 2010 Report], available at 
http://oba.od.nih.gov/oba/sacghs/ reports/SACGHS_ 
patents_report_2010.pdf.  A sole provider of a 
medical service is simply not in the best interest of 
the public health.  See Decl. of Debra Leonard, M.D., 
Ph.D., J.A. at 271–77.  Since the implications of 
incorrect genetic test results are grave, it is 
imperative that patients not be prevented from 
seeking a second opinion. 
 
C. Gene Patents Limit Access to Genetic 
Testing for Low-Income Patients 
Covered by Medicaid 
 
Patents additionally create unique issues of 
access for low-income Medicaid  recipients who need 
genetic tests.  These problems are not limited to 
Myriad’s BRCA1/2 test, but also arise with other 
genetic tests offered by patent rights holders. 
SACGHS 2010 Report, supra, at 42–44.  Gaining 
access to genetic testing is also particularly 
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challenging for Medicaid patients because gene 
patents allow exclusive rights holders to place limits 
on the forms of insurance that they will accept.  Id. at 
43.  Clinicians have reported access problems “when 
an exclusive rights holder does not accept a 
particular insurance, but enforces its patents to 
narrow or clear the market.”  Id.  Specifically, two 
Emory University genetic counselors commented that 
“there are also labs [that are exclusive licensees or 
patent holders] that choose not to contract with 
Medicaid or Medicare at all.”  Id. (brackets in 
original).  SACGHS concluded in its April 2010 
report that “patient access problems . . . are caused 
not by any behavior by health insurers, but by an 
exclusive rights holder’s decisions” and that “[i]f 
other laboratories could offer [these genetic tests], 
patients would have a greater chance of obtaining 
access [to them].”  Id. at 44–45.  A recent Kaiser 
Family Foundation State survey on preventive 
services for women under Medicaid, in which 48 
states participated, noted that while all of the 
surveyed states cover mammograms, only “about half 
(30 states) cover BRCA testing and counseling 
services for women who are a higher risk for this 
genetic mutation associated with breast cancer.” 
Kaiser Family Found., State Coverage of Preventive 
Services for Women Under Medicaid: Findings from a 
State-Level Survey 2 (2012), available at 
http://www.kff.org/womenshealth/upload/8330.pdf. 
 
With this uncertain health care framework in 
place for Medicaid beneficiaries, the access problems 
created by exclusive gene patents are acute for these 
low-income individuals. Unfortunately, even 
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Medicaid recipients who live in states that cover 
BRCA testing have difficulty getting testing because 
Myriad refuses to accept their Medicaid.  Lisbeth 
Ceriani, one of the plaintiffs, spoke candidly in the 
District Court about how Myriad Genetics holds 
Medicaid recipients’ fate and future in its 
administrative hands because it could choose to 
accept or reject her Medicaid insurance: 
 
I am currently insured through 
MassHealth, a Medicaid insurance 
program for low-income people in 
Massachusetts. Although my health 
insurance covers genetic testing done 
through contracted laboratories, 
Myriad refuses to contract with 
MassHealth. I was told that Myriad 
refuses to accept the $1599 
reimbursement rate that MassHealth 
offers for the test. Myriad is the only 
laboratory in the U.S. that provides 
full BRCA gene sequencing, so it is 
impossible for MassHealth to 
“contract” with another laboratory to 
cover this test for its insured. 
 
J.A. at 121. 
 
Access to genetic testing is also difficult for 
large segments of the Latin American/Hispanic 
population, who are disproportionately poor and 
uninsured or underinsured.  Lloyd Runser, Cabrina 
Eagan & Danielle Olds, The Uninsured and 
Underinsured, http://www.case.edu/med/epidbio/mph 
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p439/Safety_Nets.htm (last visited Jan. 29, 2013).2 
Recent data released by Myriad indicates that 
Hispanic patients who need BRCA testing need the 
full range and more costly BART analysis.  See 
Myriad Genetic Labs., Inc., BRCA1 and BRCA2 
Prevalence Tables for Mutations Detected by 
Sequencing, the 5-Site Rearrangement Panel (LRP) 
and the BRACAnalyis Large Rearrangement Test 
(BART) in High Risk Patients, 
http://www.myriad.com/lib/brac/BART-table-faq.pdf 
(last visited Jan. 24, 2013).3  These tests are in excess 
of $3000 and for full range testing can exceed $4000.  
See Myriad Genetic Labs., Inc., Advanced Beneficiary 
Notice of Non-Coverage, available at http://www. 
myriad. com/lib/abn/Myriad-ABN.pdf.  Those at risk 
for cancer often have no choice but to forgo 
potentially life-saving health care treatment because 
they lack either health care coverage or the resources 
to pay for genetic testing out-of-pocket. 
  
 
 
 
                                                            
2 See also Office of the Assistant Sec’y for Planning & 
Evaluation, U.S. Dep’t of Health & Human Servs., Overview of 
the Uninsured in the U.S.: An Analysis of the 2005 Current 
Population Survey (2005), http://aspe.hhs.gov/ 
health/reports/05/uninsured-cps/index.htm#race. 
 
3 See also Yale Cancer Genetic Counseling, An Open Letter to 
Myriad Genetics (July 22, 2011), http://yalecancergenetic 
counseling.blogspot.com/2011/07/open-letter-to-myriad-enetics. 
html. 
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II. Human Genes and Isolated DNA Are 
Products of Nature and Not Patent 
Eligible. 
The rationale for excluding human genes and 
genetic sequences rests upon the principles that:  
 
[L]aws of nature, natural phenomena, and 
abstract ideas are not patentable. 
  
Mayo Collaborative Servs. v. Prometheus Labs., 
Inc., 566 U.S. __, 132 S. Ct. 1289, 1293 (2012) 
(quoting Diamond v. Diehr, 450 U.S. 175, 185 
(1981)).  
 
The discovery of phenomena of nature, even when 
previously unknown, is not patentable.  Parker v. 
Flook, 437 U.S. 584, 593 n.15 (1978) (“Patentable 
subject matter must be new [novel]; not merely 
heretofore unknown.” (quoting Peter D. Rosenberg, 
Patent Law Fundamentals § 4 at 3 (1975)); Diamond, 
450 U.S. at 185 (excluding “laws of nature, natural 
phenomena, and abstract ideas”).  These categorical 
exclusions are soundly based on the idea that 
“[p]henomena of nature . . . mental processes, and 
abstract intellectual concepts are . . . the basic tools 
of scientific and technological work.”  Gottschalk v. 
Benson, 409 U.S. 63, 68 (1972); see Funk Bros. Seed 
Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 
(1948) (“manifestations of laws of nature [are] free to 
all men and reserved exclusively to none”); Parker, 
437 U.S. at 593 n.15 (patentable inventions must not 
be “merely heretofore unknown,” to avoid depriving 
the public of prior uses) (quoting Rosenberg, supra).  
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“In other words, natural phenomena, laws of nature, 
or abstract ideas, without more, are not considered to 
be ‘useful arts.’”  Edward C. Walterscheid, “Within 
the Limits of the Constitutional Grant”: 
Constitutional Limitations on the Patent Power, 9 J. 
Intell. Prop. L. 291, 349 (2002). 
 
These exclusions derive from the historic 
understanding that nature and science are the 
common heritage of mankind, free from 
appropriation by particular persons. 
  
If nature has made any one thing less 
susceptible than all others of exclusive 
property, it is the action of the thinking 
power called an idea . . . .  That ideas 
should freely spread from one to another 
over the globe, for the moral and mutual 
instruction of man, and improvement of 
his condition, seems to have been 
peculiarly and benevolently designed by 
nature, when she made them, like fire, 
expansible over all space, without 
lessening their density in any point . . . . 
  
Letter from Thomas Jefferson to Isaac McPherson 
(Aug. 13, 1813), in 13 The Writings of Thomas 
Jefferson 326, 333–34 (Albert Ellery Bergh ed., 1908). 
  
In Funk Bros., 333 U.S. at 132, the Court held 
that an inventor claiming a bacterial species that 
exhibited the property of mutual non-inhibition could 
not patent the bacteria, since it was merely a claim 
for a natural phenomena.  Id. at 130.  Nor was the 
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combining of six types of bacteria into one product—
bacteria whose individual function had only been 
“discovered” and not “invented”— patentable.  Id. at 
132.  As the Court noted: 
 
There is, of course, an advantage in the 
combination. . . . But a product must be 
more than new and useful to be 
patented; it must also satisfy the 
requirements of invention or discovery. 
The application of this newly-discovered 
natural principle to the problem of 
packaging of inoculants may well have 
been an important commercial advance. 
But once nature’s secret of the non-
inhibitive quality of certain strains of 
the species of Rhizobium was 
discovered, the state of the art made the 
production of a mixed inoculant a simple 
step. Even though it may have been the 
product of skill, it certainly was not the 
product of invention. There is no way in 
which we could call it such unless we 
borrowed invention from the discovery 
of the natural principle itself.  
 
Id. at 131–32 (citations omitted). 
 
Physical steps such as isolating and removing 
DNA cannot transform unpatentable natural 
phenomena into a patentable invention.  Likewise 
in American Wood-Paper Co. v. Fibre Disintegrating 
Co., 90 U.S. 566 (1874), the Court found that merely 
removing pulp from straw, wood, or other natural 
14 
 
 
 
sources did not make it a patentable new composition 
of matter: “A process to obtain it [an extract] from a 
subject from which it has never been taken may be 
the creature of invention, but the thing itself when 
obtained cannot be called a new manufacture.”  Am. 
Wood-Paper, 90 U.S. at 593–94.  
 
In that case, American Wood-Paper sought to 
patent a supposedly “new” type of pulp that was 
better suited for the manufacture of paper than the 
then-existing pulp.  Id. at 577.  All pulp contains both 
cellulose and “intercellular matter,” the latter of 
which must be removed to render the cellulose fit for 
being made into paper.  Id. at 566.  Up until this 
point, all pulp was removed by applying both 
chemical and mechanical treatment; however, 
American Wood-Paper managed to remove the 
intercellular matter using chemical means alone.  Id.  
American Wood-Paper claimed that the pulp 
produced by mere chemical treatment alone was a 
“new manufacture,” and thus, eligible for patent 
protection.  Id. at 595.  
 
The Court rejected the patent, holding that the 
new pulp was “not a new composition of 
matter.”  Id. at 593.  The Court held as immaterial 
the fact that the new pulp was pure cellulose 
whereas the old pulp was only “approximately pure,” 
i.e. it was still mixed with intercellular matter.  Id. at 
594. 
 
  Isolated human genes and DNA sequences are 
products of nature and are not patentable. 
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CONCLUSION 
 
For the foregoing reasons, AARP respectfully 
urges the Court to grant the relief requested by 
petitioners and invalidate the patents. 
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